Researchers at Queen Mary University of London examined cervical cancer mortality figures for England spanning 2001 to 2024. Their findings, published in The Lancet, reveal a clear association between the HPV vaccination programme and a substantial drop in deaths among those eligible for the jab as adolescents.
The programme began in 2008, offering the vaccine routinely to girls aged 12 to 13. Uptake reached between 88 and 90 percent. Data now show that no cervical cancer deaths occurred in women aged 20 to 24 in England from 2020 to 2024. That outcome represents a 100 percent reduction against 23.1 deaths that would have been expected had pre-vaccination trends from 2000 to 2014 continued.
An 80 percent reduction in mortality for the same age group had already appeared between 2015 and 2019. Among women aged 25 to 29, deaths fell by 69 percent in the period from 2020 to 2024. Across all affected cohorts up to the end of 2024 the programme is linked to 199.6 fewer cervical cancer deaths, with a 95 percent confidence interval of 125.0 to 274.2.
Prof Peter Sasieni, who led the research with Milena Falcaro, stated in the paper's interpretation: "Our findings provide the first robust national-level evidence, albeit observational, that high HPV vaccination coverage is associated with a substantial reduction in cervical cancer deaths." The analysis relied on Poisson regression of population-level data, comparing observed deaths against projections drawn from earlier trends. It focused on birth cohorts that entered the school-based scheme.
The study recorded the largest gains in the youngest vaccinated groups. As these cohorts grow older, further marked declines in cervical cancer mortality are anticipated. Sasieni added in the paper's conclusions: "These findings support the achievability of the WHO goal of eliminating cervical cancer as a public health problem, and efforts should be made to achieve high vaccine uptake among young adolescents globally."
In remarks released with the publication he observed: "It is incredible to think that a single jab can almost eliminate a particular type of cancer." Such results underline the protective power of timely, targeted preventive measures. They demonstrate measurable gains in safeguarding the health of young women without requiring broader state intrusion into personal decisions.
